Close Lucintel Chat
Didn't Find What You're Looking for?
Call us at +1972 636 5056 or write at helpdesk@Lucintel.com
Ask an Expert Provide Custom Requirements Download Sample Report Search Available Reports
  • helpdesk@Lucintel.com
  • |
  • Call Lucintel +1 972 636 5056
  • |
  • Login
  • |
  • Register
  • |
  • Search
  • |
'
...

The Impact of COVID-19 is included in Targeted Protein Degrader Market Report. Buy it today to get an advantage.

Request the impact of COVID-19 on your product or industry


Targeted Protein Degrader Market Trends and Forecast

The future of the global targeted protein degrader market looks promising with opportunities in the prostate cancer, breast cancer, and lymphoma markets. The global targeted protein degrader market is expected to grow with a CAGR of 24.3% from 2024 to 2030. The major drivers for this market are increasing prevalence of cancer & neurodegenerative diseases and rising demand for targeted therapies with fewer side effects.
• Lucintel forecasts that molecular glue is expected to witness the highest growth over the forecast period.
• Within this market, prostate cancer is expected to witness the highest growth.
• APAC is expected to witness the highest growth over the forecast period.

Targeted Protein Degrader Market Trends and Forecast

Country Wise Outlook for the Targeted Protein Degrader Market

• United States: Arvinas announced a strategic partnership with Pfizer to advance protein degrader therapies, focusing on expanding clinical trials for cancer treatments.

• United Kingdom: GlaxoSmithKline launched a new research initiative to develop targeted protein degraders for neurodegenerative diseases, aiming for clinical trial commencement by 2025.

• Japan: Takeda Pharmaceuticals secured government funding to accelerate the development of protein degraders for rare diseases, enhancing their R&D capabilities.

• Germany: Boehringer Ingelheim announced the initiation of clinical trials for a novel protein degrader, targeting difficult-to-treat cancers, with government support for innovative therapies.


A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.

Targeted Protein Degrader Market by Segment

Targeted Protein Degrader Market by Segment

The study includes a forecast for the global targeted protein degrader market by type, application, and region.

Targeted Protein Degrader Market by Type [Value from 2018 to 2030]:


• Molecular Glues
• Ligand-Directed Degraders
• Antibody Drug Conjugate Degraders

Targeted Protein Degrader Market by Application [Value from 2018 to 2030]:


• Prostate Cancer
• Breast Cancer
• Lymphoma
• Others

Targeted Protein Degrader Market by Region [Value from 2018 to 2030]:


• North America
• Europe
• Asia Pacific
• The Rest of the World

List of Targeted Protein Degrader Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies targeted protein degrader companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the targeted protein degrader companies profiled in this report include-
• Arvinas
• Kymera Therapeutics
• Dialectic Therapeutics
• Bristol-Myers Squibb
• Nurix
• Cullgen
• C4 Therapeutics
• Foghorn
• Novartis
• Pfizer

Recent Development in the Targeted Protein Degrader Market

• C4 Therapeutics: C4 Therapeutics has made significant progress in its clinical trials for CFT7455, a novel protein degrader designed to treat hematologic malignancies. The company reported promising early-phase results and plans to expand its clinical program to include additional cancer indications.

• Nurix Therapeutics: Nurix Therapeutics has entered into a collaboration with Gilead Sciences to develop targeted protein degraders for cancer and other diseases. This partnership combines Nurix’s expertise in E3 ligase biology with Gilead’s strengths in drug development, aiming to bring innovative treatments to market.

• Kymera Therapeutics: Kymera Therapeutics has announced the successful completion of a Series C funding round, raising $102 million to advance its pipeline of protein degrader therapies. The company focuses on developing treatments for autoimmune diseases and cancer, with multiple candidates in preclinical and clinical stages.

• AstraZeneca: AstraZeneca is investing in the development of targeted protein degraders as part of its broader strategy to expand its oncology portfolio. The company is exploring collaborations and partnerships to leverage cutting-edge technologies and accelerate the development of novel cancer therapies.



Features of the Global Targeted Protein Degrader Market

Market Size Estimates: Targeted protein degrader market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
Segmentation Analysis: Targeted protein degrader market size by type, application, and region in terms of value ($B).
Regional Analysis: Targeted protein degrader market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the targeted protein degrader market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the targeted protein degrader market.
Analysis of competitive intensity of the industry based on Porter’s Five Forces model.

FAQ

Q1. What is the growth forecast for targeted protein degrader market?
Answer: The global targeted protein degrader market is expected to grow with a CAGR of 24.3% from 2024 to 2030.
Q2. What are the major drivers influencing the growth of the targeted protein degrader market?
Answer: The major drivers for this market are increasing prevalence of cancer & neurodegenerative diseases and rising demand for targeted therapies with fewer side effects.
Q3. What are the major segments for targeted protein degrader market?
Answer: The future of the targeted protein degrader market looks promising with opportunities in the prostate cancer, breast cancer, and lymphoma markets.
Q4. Who are the key targeted protein degrader market companies?
Answer: Some of the key targeted protein degrader companies are as follows:
• Arvinas
• Kymera Therapeutics
• Dialectic Therapeutics
• Bristol-Myers Squibb
• Nurix
• Cullgen
• C4 Therapeutics
• Foghorn
• Novartis
• Pfizer
Q5. Which targeted protein degrader market segment will be the largest in future?
Answer: Lucintel forecasts that molecular glue is expected to witness the highest growth over the forecast period.
Q6. In targeted protein degrader market, which region is expected to be the largest in next 5 years?
Answer: APAC is expected to witness the highest growth over the forecast period.
Q7. Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

Q.1. What are some of the most promising, high-growth opportunities for the targeted protein degrader market by type (molecular glues, ligand-directed degraders, and antibody drug conjugate degraders), application (prostate cancer, breast cancer, lymphoma, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

For any questions related to Targeted Protein Degrader Market Market, Targeted Protein Degrader Market Market Size, Targeted Protein Degrader Market Market Growth, Targeted Protein Degrader Market Market Analysis, Targeted Protein Degrader Market Market Report, Targeted Protein Degrader Market Market Share, Targeted Protein Degrader Market Market Trends, Targeted Protein Degrader Market Market Forecast, Targeted Protein Degrader Market Companies, write Lucintel analyst at email: helpdesk@lucintel.com. We will be glad to get back to you soon.
Table of Contents

1. Executive Summary
2. Global Targeted Protein Degrader Market : Market Dynamics
2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges 
3. Market Trends and Forecast Analysis from 2018 to 2030
3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
3.2. Global Targeted Protein Degrader Market Trends (2018-2023) and Forecast (2024-2030)
3.3: Global Targeted Protein Degrader Market by Type
3.3.1: Molecular Glues
3.3.2: Ligand-Directed Degraders
3.3.3: Antibody Drug Conjugate Degraders
3.4: Global Targeted Protein Degrader Market by Application
3.4.1: Prostate Cancer
3.4.2: Breast Cancer
3.4.3: Lymphoma
3.4.4: Others
4. Market Trends and Forecast Analysis by Region from 2018 to 2030
4.1: Global Targeted Protein Degrader Market by Region
4.2: North American Targeted Protein Degrader Market
4.2.1: North American Targeted Protein Degrader Market by Type: Molecular Glues, Ligand-Directed Degraders, and Antibody Drug Conjugate Degraders
4.2.2: North American Targeted Protein Degrader Market by Application: Prostate Cancer, Breast Cancer, Lymphoma, and Others
4.3: European Targeted Protein Degrader Market
4.3.1: European Targeted Protein Degrader Market by Type: Molecular Glues, Ligand-Directed Degraders, and Antibody Drug Conjugate Degraders
4.3.2: European Targeted Protein Degrader Market by Application: Prostate Cancer, Breast Cancer, Lymphoma, and Others
4.4: APAC Targeted Protein Degrader Market
4.4.1: APAC Targeted Protein Degrader Market by Type: Molecular Glues, Ligand-Directed Degraders, and Antibody Drug Conjugate Degraders
4.4.2: APAC Targeted Protein Degrader Market by Application: Prostate Cancer, Breast Cancer, Lymphoma, and Others
4.5: ROW Targeted Protein Degrader Market
4.5.1: ROW Targeted Protein Degrader Market by Type: Molecular Glues, Ligand-Directed Degraders, and Antibody Drug Conjugate Degraders
4.5.2: ROW Targeted Protein Degrader Market by Application: Prostate Cancer, Breast Cancer, Lymphoma, and Others
5. Competitor Analysis
5.1: Product Portfolio Analysis
5.2: Operational Integration
5.3: Porter’s Five Forces Analysis
6. Growth Opportunities and Strategic Analysis
6.1: Growth Opportunity Analysis
6.1.1: Growth Opportunities for the Global Targeted Protein Degrader Market by Type
6.1.2: Growth Opportunities for the Global Targeted Protein Degrader Market by Application
6.1.3: Growth Opportunities for the Global Targeted Protein Degrader Market by Region
6.2: Emerging Trends in the Global Targeted Protein Degrader Market
6.3: Strategic Analysis
6.3.1: New Product Development
6.3.2: Capacity Expansion of the Global Targeted Protein Degrader Market
6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Targeted Protein Degrader Market
6.3.4: Certification and Licensing
7. Company Profiles of Leading Players
7.1: Arvinas
7.2: Kymera Therapeutics
7.3: Dialectic Therapeutics
7.4: Bristol-Myers Squibb
7.5: Nurix
7.6: Cullgen
7.7: C4 Therapeutics
7.8: Foghorn
7.9: Novartis
7.10: Pfizer
.

Buy full report or by chapter as follows

Price by License Type:
[-] Hide Chapter Details
[Chapter Number] [Chapter Name] [Chapter Number Of Pages] [Chapter Price]
Title/Chapter Name Pages Price
Full Report: Targeted Protein Degrader Market Report: Trends, Forecast and Competitive Analysis to 2030 Full Report $ 4,850
A 150 Page Report
Lucintel has been in the business of market research and management consulting since 2000 and has published over 1000 market intelligence reports in various markets / applications and served over 1,000 clients worldwide. This study is a culmination of four months of full-time effort performed by Lucintel's analyst team. The analysts used the following sources for the creation and completion of this valuable report:
  • In-depth interviews of the major players in this market
  • Detailed secondary research from competitors’ financial statements and published data 
  • Extensive searches of published works, market, and database information pertaining to industry news, company press releases, and customer intentions
  • A compilation of the experiences, judgments, and insights of Lucintel’s professionals, who have analyzed and tracked this market over the years.
Extensive research and interviews are conducted across the supply chain of this market to estimate market share, market size, trends, drivers, challenges, and forecasts. Below is a brief summary of the primary interviews that were conducted by job function for this report.
 
Thus, Lucintel compiles vast amounts of data from numerous sources, validates the integrity of that data, and performs a comprehensive analysis. Lucintel then organizes the data, its findings, and insights into a concise report designed to support the strategic decision-making process. The figure below is a graphical representation of Lucintel’s research process. 
 

Please sign in below to get report brochure - Targeted Protein Degrader Market Report.

At Lucintel, we respect your privacy and maintain the confidentiality of information / data provided by you
(Please enter your corporate email. * These fields are mandatory )